Authenticating with LexisNexis

Life Sciences

  • May 28, 2026

    Trans Patients Say Stanford Can't Give DOJ Medical Records

    A group of transgender adolescents who received gender-related care at a Stanford Medicine hospital urged a California federal court to order the hospital not to turn over any of their medical records in response to a criminal subpoena issued by a grand jury in Texas.

  • May 28, 2026

    Injury Law Roundup: Freight Brokers, Uber Lose Key Cases

    The U.S. Supreme Court's green light of negligent hiring claims against freight brokers in highway crash cases and an adverse verdict against Uber in the sexual assault multidistrict litigation lead Law360's Injury Law Roundup.

  • May 28, 2026

    Hospital Operator, Execs Ink $32M FCA Settlement With Feds

    Psychiatric hospital operator Oglethorpe Inc. has agreed to pay $32 million and be excluded from all federal healthcare programs for 10 years to resolve allegations it knowingly failed to return Medicare overpayments in violation of the False Claims Act.

  • May 28, 2026

    McDermott-Led Ampersand Clinches $1.5B Fund

    Healthcare-focused private equity firm Ampersand Capital Partners, advised by McDermott Will & Schulte, on Thursday revealed that it closed its latest fund with $1.5 billion.

  • May 28, 2026

    3 Federal Circuit Clashes To Watch In June

    The Federal Circuit's argument calendar next month includes a dispute between Micron and Netlist over Idaho's law against "bad faith" patent suits, and appeals of multimillion-dollar verdicts against Boston Scientific on a stent patent and TP-Link on Wi-Fi patents.

  • May 28, 2026

    Zoetis Hit With Investor Suit Over Slowed Pet Drug Sales

    Animal health company Zoetis Inc. has been hit with a proposed shareholder class action accusing it of misleading investors about its growth prospects amid rising competition and shifting trends in the veterinary industry.

  • May 28, 2026

    J&J Unit Cleared In Blood Pump Patent Suit In Mass.

    A Massachusetts federal jury on Thursday cleared a Johnson & Johnson MedTech subsidiary of allegations that it infringed a blood pump patent owned by a unit of Swedish medical device company Getinge AB.

  • May 28, 2026

    Chancery Tosses Insider Financing Suit Against Ayala Brass

    The Delaware Chancery Court has dismissed a stockholder derivative suit against several venture capital investors and directors of biotechnology company Ayala Pharmaceuticals Inc., ruling that the plaintiff failed to show the board could not independently evaluate litigation over a disputed 2023 financing deal.

  • May 28, 2026

    Abbott Labs Settles Ill. Genetic Privacy Suit

    Abbott Laboratories has inked a settlement with a proposed class of workers alleging the company's onboarding materials asked for employees' medical history in violation of an Illinois law aimed at protecting residents' genetic information, prompting an Illinois federal judge to dismiss the case Thursday.

  • May 28, 2026

    Legislative Update: Cannabis And Psychedelics Bill Roundup

    Tennessee became the latest state to approve a policy paving the way for more research into ibogaine; Vermont lawmakers brought a bill doubling cannabis potency and possession limits closer to the finish line; and California legislators approved a bill banning the sale of "laughing gas" used for recreational purposes. Here are the major moves in cannabis and psychedelics legislation from the past week.

  • May 28, 2026

    Husch Blackwell Adds Manatt Healthcare Duo In LA

    Husch Blackwell LLP announced that a pair of Los Angeles-based commercial litigators from Manatt Phelps & Phillips LLP have joined the firm as part of its focus on expanding its California healthcare capabilities.

  • May 28, 2026

    Ex-Reebok CEO Says Biotech Investor Suit Was Shakedown

    Former Reebok CEO and billionaire philanthropist Paul Fireman said a "baseless" shareholder lawsuit against him and a biotech company he later sold to Janssen Pharmaceuticals Inc. for $85 million was an effort to get him to "cave" to demands for more money, according to a complaint filed in Massachusetts state court Wednesday.

  • May 28, 2026

    9th Circ. Won't Revisit FCA Ruling Over Drug Price Program

    The Ninth Circuit has said it will not disturb its March ruling allowing a hospital chain to pursue a False Claims Act lawsuit against various pharmaceutical companies for allegedly causing the government to overpay for drugs under a discount program.

  • May 28, 2026

    Split Fed. Circ. Says $452M Trade Secret Case Was Untimely

    A split Federal Circuit panel on Thursday erased Insulet Corp.'s trade secret victory against EOFlow Co. Ltd., holding that the medical device maker filed its claims too late and reversing a $452 million jury verdict that was later reduced to $59.4 million.

  • May 27, 2026

    Pharmacies Beat Fla. Hospitals' Opioids Suit

    A Florida state judge has handed Walmart, Walgreens and CVS a win in a fight with hospitals over treatment of opioid-addicted patients, finding the hospitals cannot recover damages under state racketeering law because their injuries are indirect.

  • May 27, 2026

    Inovio Brass Hit With Suit Over FDA Approval Claims

    Executives and directors of Inovio Pharmaceuticals Inc. on Wednesday were slapped with a shareholder derivative suit accusing them of damaging the company with misleading statements regarding the likelihood that the U.S. Food and Drug Administration would grant priority review to its DNA medicine.

  • May 27, 2026

    3 Generic Drug Antitrust Deals Totaling $17.9M Get Final Nod

    A Connecticut federal judge on Wednesday gave final approval to a $17.9 million generic drug price-fixing settlement between pharmaceutical companies Bausch Health US LLC, Bausch Health Americas Inc., and Lannett Co. Inc. and 48 states, territories, and governments, finding the terms reasonable despite an objection.

  • May 27, 2026

    ProPublica Denied Access To Ranbaxy Antitrust MDL Docs

    A Massachusetts federal court denied ProPublica's bid to unseal court filings in settled multidistrict litigation alleging a subsidiary of Indian drugmaker Sun Pharmaceuticals illegally delayed market entry of generic drugs, ruling the nonprofit news organization's request came too late in the case.

  • May 27, 2026

    Pharmacies Hit With Injunction In Gilead Counterfeit Drug Row

    A New York federal judge has issued a preliminary injunction blocking a pair of Queens pharmacies from selling any human immunodeficiency virus medications that bear the Gilead name or the name of two of its products.

  • May 27, 2026

    NJ Justices Revive Eye Injury Suit For 'Gatekeeping' Test

    The Supreme Court of New Jersey revived a woman's suit alleging she suffered serious eye injuries because of a defect in Allergan USA Inc.'s product Ozurdex, ruling Wednesday that the trial court failed to conduct the gatekeeping inquiry required when there is a dispute over the reliability of expert testimony.

  • May 27, 2026

    Stock Trade Co. Wants Out Of Mallinckrodt Clawback Suit

    A high-frequency stock trading firm is asking a Delaware bankruptcy judge to make it the latest defendant dismissed from a bid by Mallinckrodt PLC to recover $1.6 billion paid for stock buybacks before the opioid distributor's bankruptcy.

  • May 27, 2026

    Squires Institutes 3 IPRs, Refuses Case With Limited Impact

    U.S. Patent and Trademark Office Director John Squires granted three petitions for inter partes review in his newest bulk order and broke down why he previously rejected CyberSecure IPS LLC's challenge to a Network Integrity Systems Inc. optical fibers monitoring patent.

  • May 27, 2026

    Squires Says Sun PGR Petition Denied For Not Naming Parent

    Sun Pharmaceutical Industries Inc.'s failure to name its parent company in its challenge to a Biofrontera Inc. patent was why its request for review was rejected early, U.S. Patent and Trademark Office Director John Squires has said.

  • May 27, 2026

    Pierce Atwood Rips Billionaire's 'Absurd' Suit Over Asset Sale

    Pierce Atwood and two attorneys urged a Massachusetts federal judge to reject a Ukrainian billionaire's suit blaming them for a $1.8 million damages order in investor litigation over the billionaire's failed biotech company, saying his own wrongdoing led to the judgment.

  • May 26, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court this past week handled a broad mix of cross-border corporate control disputes, merger settlements, startup equity fights, advancement claims and board oversight litigation, while also weighing fallout from high-profile deals involving Microsoft Corp., The Boeing Co. and Nikola Corp.

Expert Analysis

  • 4 Developments That Defined The 2025 Ethics Landscape

    Author Photo

    The legal profession spent 2025 at the edge of its ethical comfort zone as courts, firms and regulators confronted how fast-moving technologies and new business models collide with long-standing professional duties, signaling that the profession is entering a period of sustained disruption that will continue into 2026, says Hilary Gerzhoy at HWG Law.

  • Navigating AI In The Legal Industry

    Author Photo

    As artificial intelligence becomes an increasingly integral part of legal practice, Law360 guest commentary this year examined evolving ethical obligations, how the plaintiffs bar is using AI to level the playing field against corporate defense teams, and the attendant risks of adoption.

  • How Fractional GCs Can Manage Risks Of Engagement

    Author Photo

    As more organizations eliminate their in-house legal departments in favor of outsourcing legal work, fractional general counsel roles offer practitioners an engaging and flexible way to practice at a high level, but they can also present legal, ethical and operational risks that must be proactively managed, say attorneys at Boies Schiller.

  • 2025 Legal Milestones That Will Shape Psychedelics Sector

    Author Photo

    As 2025 draws to a close, psychedelic drug development stands at an inflection point, experiencing unprecedented momentum through recent sweeping regulatory changes and landmark clinical milestones, amid rapidly evolving regulatory expectations, say Odette Hauke at Odette Alina LLC and Kimberly Chew at Husch Blackwell.

  • Series

    Nature Photography Makes Me A Better Lawyer

    Author Photo

    Nature photography reminds me to focus on what is in front of me and to slow down to achieve success, and, in embracing the value of viewing situations through different lenses, offers skills transferable to the practice of law, says Brian Willett at Saul Ewing.

  • What Defense Teams Must Know About PFAS Testing Methods

    Author Photo

    Whether testing for per- and polyfluoroalkyl substances produces results meaningful for litigation depends on the validity of the sampling methodology — so effectively defending these claims requires understanding the scientific and legal implications of different PFAS testing protocols, say attorneys at Hollingsworth.

  • Series

    Law School's Missed Lessons: Practical Problem Solving

    Author Photo

    Issue-spotting skills are well honed in law school, but practicing attorneys must also identify clients’ problems and true goals, and then be able to provide solutions, says Mary Kate Hogan at Quarles & Brady.

  • Intellectual Property Challenges In AI-Driven Drug Discovery

    Author Photo

    Given the adoption of artificial intelligence-based drug discovery platforms and the U.S. Patent and Trademark Office's recent guidance on determining inventorship in AI-assisted inventions, practitioners must consider unprecedented questions regarding inventorship, patentability standards and infringement liability, says Paul Calvo at Sterne Kessler.

  • Reel Justice: 'The Mastermind' And Juror Decision-Making

    Author Photo

    The recent art heist film “The Mastermind” forces viewers to discern the protagonist’s ambiguous motives and reconcile contradictions, offering lessons for attorneys about how a well-crafted trial narrative can tap into the psychological phenomena underlying juror decision-making, says Veronica Finkelstein at Wilmington University.

  • Learning From 2025 FCA Trends Targeting PE In Healthcare

    Author Photo

    False Claims Act enforcement trends and legislative developments from this year signal intensifying state and federal scrutiny of private equity's growing footprint in healthcare, and the urgency of compliance, says Lisa Re at Arnold & Porter.

  • Software Patents May Face New Eligibility Scrutiny

    Author Photo

    November guidance from the U.S. Patent and Trademark Office, along with recent litigation trends from the Federal Circuit, may encourage new challenges in the USPTO and district courts to artificial intelligence and software patents that rely on generic computing functions without concrete details, say attorneys at Venable.

  • Opinion

    A Uniform Federal Rule Would Curb Gen AI Missteps In Court

    Author Photo

    To address the patchwork of courts’ standing orders on generative artificial intelligence, curbing abuses and relieving the burden on judges, the federal judiciary should consider amending its civil procedure rules to require litigants to certify they’ve reviewed legal filings for accuracy, say attorneys at Shook Hardy.

  • Riding The Changing Winds For AI Innovations At The USPTO

    Author Photo

    As recent U.S. Patent and Trademark Office moves reshape how artificial intelligence inventions will be examined and put them on firmer eligibility footing, practitioners need to consider how this shift is both an opportunity and a challenge, say Ryan Phelan at Marshall Gerstein and attorney Mark Campagna.

  • Series

    The Law Firm Merger Diaries: Integrating Practice Groups

    Author Photo

    Enacting unified leadership and consistent client service standards ensures law firm practice groups connect and collaborate around shared goals, turning a law firm merger into a platform for growth rather than a period of disruption, says Brian Catlett at Fennemore Craig.

  • Opinion

    Supreme Court Term Limits Would Carry Hidden Risk

    Author Photo

    While proposals for limiting the terms of U.S. Supreme Court justices are popular, a steady stream of relatively young, highly marketable ex-justices with unique knowledge and influence entering the marketplace of law and politics could create new problems, say Michael Broyde at Emory University and Hayden Hall at the U.S. Bankruptcy Court for the District of Delaware.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.